Table 1 Correlation between secreted USP25 levels in NSCLC patients and their clinicopathologic characteristics
Clinical pathology | USP25 levels (IHC) | N | P value | ||
|---|---|---|---|---|---|
–+ | + + | + + +-+ + + + | |||
Gender | |||||
 Male | 54(29.2) | 49(26.5) | 82(44.3) | 185 | 0.0066* |
 Female | 10(14.1) | 18(25.4) | 43(60.5) | 71 | |
Age | |||||
 ≦63 | 30(21.9) | 34(24.8) | 73(53.3) | 137 | 0.0985 |
 >63 | 34(28.6) | 34(28.6) | 51(42.8) | 119 | |
Tumor size (cm) | |||||
 <3.5 | 19(20.6) | 16(17.4) | 57(62) | 92 | 0.012* |
 3.5-6 | 25(25) | 32(32) | 43(43) | 100 | |
 >6 | 20(31.3) | 19(29.7) | 25(39) | 64 | |
Histological grade | |||||
 Ι/Ι-Π| 15(36.6) | 13(31.7) | 13(31.7) | 41 | 0.0002* |
 Π| 33(27) | 38(31.1) | 51(41.9) | 122 | |
 Π-Ш/Ш | 16(17.2) | 16(17.2) | 61(65.6) | 93 | |
Clinical Stage | |||||
 1AB | 26(41.3) | 12(19) | 25(39.7) | 63 | 0.0062* |
 2AB | 23(20.4) | 35(31) | 55(48.7) | 113 | |
 3AB/4 | 15(18.7) | 20(25) | 45(56.3) | 80 | |
Lymph node status | |||||
 Metastasis | 24(15.4) | 42(26.9) | 90(57.7) | 156 | <0.0001* |
 No metastasis | 40(40) | 25(25) | 35(35) | 100 | |
Carcinoma | |||||
 Primary | 64(25) | 67(26.2) | 125(48.9) | 256 | <0.0001* |
 Adjacent | 132(51.6) | 123(48) | 1(0.4) | 256 | |